TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
Rainer Fagerholm, Sofia Khan, Marjanka K Schmidt, Montserrat Garcia-Closas, Pavi Heikkila, Jani Saarela, Jonathan Beesley, Maral Jamshidi, Kristiina Aittomaki, Jianjun Liu, H Raza Ali, Irene L Andrulis, Matthias W Beckmann, Sabine Behrens, Fiona M Blows, Hermann Brenner, Jenny Chang-Claude, Fergus J Couch, Kamila Czene, Peter A Fasching Show all
Oncotarget | IMPACT JOURNALS LLC | Published : 2017
Awarded by Cancer Research UK
Awarded by European Community's Seventh Framework Programme
Awarded by National Institutes of Health
Awarded by Post-Cancer GWAS initiative
Awarded by Department of Defence
Awarded by National Cancer Institute (USA)
Awarded by Dutch Cancer Society
Awarded by Academy of Finland
Awarded by United States Army Medical Research and Materiel Command
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by 'Stichting tegen Kanker'
Awarded by Deutsche Krebshilfe e.V.
Awarded by Federal Ministry of Education and Research (BMBF) Germany
Awarded by NIH
Awarded by NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer
Awarded by Academy of Medical Sciences (AMS)
Awarded by National Institute for Health Research
The Breast Cancer Association Consortium (BCAC) is funded by Cancer Research UK [C1287/A10118, C1287/A12014] and by the European Community's Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). Funding for the iCOGS genotyping infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.The Australian Breast Cancer Family Study (ABCFS; John L. Hopper, Melissa C. Southey) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow.The ABCS study (Marjanka K. Schmidt, Renske Keeman) was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363].The work of the BBCC (Matthias W. Beckmann, Peter A. Fasching) was partly funded by ELAN-Fond of the University Hospital of Erlangen.The ESTHER study (Hermann Brenner, Bernd Holleczek) was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe).The HEBCS (Rainer Fagerholm, Sofia Khan, Paivi Heikkila, Maral Jamshidi, Kristiina Aittomaki, Carl Blomqvist, Heli Nevanlinna) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, The Nordic Cancer Union, and the Sigrid Juselius Foundation.Financial support for KARBAC (Annika Lindblom, Sara Margolin) was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation.The KBCP (Veli-Matti Kosma, Arto Mannermaa) was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland.kConFab (Jonathan Beesley, Georgia ChenevixTrench) is supported by a grant from the National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. Financial support for the AOCS was provided by the United States Army Medical Research and Materiel Command [DAMD17-01-1-0729], Cancer Council Victoria, Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; 400413, 400281, 199600). G.C.T. and P.W. are supported by the NHMRC. RB was a Cancer Institute NSW Clinical Research Fellow.LMBC (Giuseppe Floris, Diether Lambrechts) is supported by the 'Stichting tegen Kanker' (232-2008 and 196-2010). Diether Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII.The MARIE study (Sabine Behrens, Jenny Chang-Claude) was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402].The MCBCS (Fergus J. Couch, Emily Hallberg) was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation.The Ontario Familial Breast Cancer Registry (OFBCR; Irene L. Andrulis, Gord Glendon) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR.The PBCS (Montserrat Garcia-Closas, Jonine Figueroa) was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA.The RBCS (Maartje J. Hooning, Agnes Jager) was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318).The SASBAC (Kamila Czene, Per Hall) study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation.SEARCH (H. Raza Ali, Fiona M. Blows, Qi Guo, Elena Provenzano, Mitul Shah) is funded by a programme grant from Cancer Research UK [C490/A10124] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge.SKKDKFZS (Ute Hamann, Maria Kabisch) is supported by the DKFZ.